Skip to Content

Spectrum Pharmaceuticals, Inc.

Merger

  • Date:
  • 4/25/2023
  • Company Name:
  • Spectrum Pharmaceuticals, Inc.
  • Stock Symbol:
  • SPPI
  • Company Name - Buyer:
  • Assertio Holdings, Inc.
  • Stock Symbol - Buyer:
  • ASRT
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 4/25/2023

Case Finder

Locate any case using the tools below.

NEW YORK, April 25, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Assertio Holdings, Inc. (NASDAQ: ASRT) (“Assertio”).

On April 25, 2023, Spectrum announced that it had entered into an agreement to be acquired by Assertio in a stock and CVR deal. Pursuant to the merger agreement, Spectrum shareholders will receive: (1) 0.1783 shares of Assertio common stock for each share of Spectrum common stock they own; and (2) one contingent value right per Spectrum share for the right to receive $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $175 million during the calendar year ending December 31, 2024, and $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $225 million during the calendar year ending December 31, 2025. The deal is expected to close in the third quarter of 2023.

Bragar Eagel & Squire is concerned that Spectrum’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Spectrum’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Spectrum Pharmaceuticals. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: